p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2529-2537

  Winthrop, Michelle D ^a,c   DeNardo, Sally J ^a   Muenzer, Jared T ^a   Chi, Sung Gil ^a,b   Gumerlock, Paul H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kyung Hee University Hospital   (South Korea)

^c Molecular Cancer Institute   (United States)

Author keywords

Apoptosis; Bcl 2; Breast carcinoma; P53; Poly(ADP ribose) polymerase (PARP); Radioimmunotheraphy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID PEPTIDE MONOCLONAL ANTIBODY Y 90; MONOCLONAL ANTIBODY Y 90; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST CARCINOMA; CANCER GRAFT; CANCER REGRESSION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RADIATION DOSE; RADIOIMMUNOTHERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0031471671     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2529::aid-cncr27>3.0.co;2-d     Document Type: Conference Paper

References (73)

1. Sakakura C, Sweeney EA, Shirahama T, Igarashi Y, Hakomori S, Nakatani H, et al. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int J Cancer 1996;67:101-05.
2. Hain J, Weller EM, Jung T, Burkart W. Effects of ionizing- and UV B-radiation on proteins controlling cell cycle progression in human cells: comparison of the MCF-7 adenocarcinoma and the SCL-2 squamous cell carcinoma cell line. Int J Radiat Oncol Biol Phys 1996;70:261-71.
3. Abend M, Gilbertz KP, Rhein A, van Beuningen D. Early and late G2 arrest of cells undergoing radiation-induced apoptosis or micronucleation. Cell Prolif 1996;29:101-13.
4. Meyn RE, Stephens LC, Mason KA, Medina D. Radiation-induced apoptosis in normal and pre-neoplastic mammary glands in vivo: significance of gland differentiation and p53 status. Int J Cancer 1996;65:466-72.
5. McAlear MA, Tuffo KM, Holm C. The large subunit of replication factor C (Rfc1p/Cdc44p) is required for DNA replication and DNA repair in saccharomyces cerevisiae. Genetics 1996;142:65-78.
6. Servomaa K, Kiuru A, Grenman R, Pekkola-Heino K, Pulkkinen JO, Rytomaa T. p53 mutations associated with increased sensitivity to ionizing radiation in human head and neck cancer cell lines. Cell Prolif 1996;29:219-30.
7. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
8. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
9. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
10. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 1990;62:671-80.
11. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491-5.
12. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362: 849-52.
13. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, et al. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 1994;54:5824-30.
14. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
15. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995;55:2910-9.
16. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
17. Schnier JB, Nishi K, Goodrich DW, Bradbury EM. G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A 1996;93:5941-6.
18. Dou QP, An B, Will PL. Induction of a retinoblastoma phosphatase activity by anticancer drugs accompanies p53-independent G1 arrest and apoptosis. Proc Natl Acad Sci U S A 1995;92:9019-23.
19. Zhan Q, Bae I, Kastan MB, Fornace AJJ. The p53-dependent gamma-ray response of GADD45. Cancer Res 1994;54:2755-60.
20. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
21. Papathanasiou MA, Kerr NC, Robbins JH, McBride OW, Alamo IJ, Barrett SF, et al. Induction by ionizing radiation of the gadd45 gene in cultured human cells: lack of mediation by protein kinase C. Mol Cell Biol 1991;11:1009-16.
22. Chen IT, Akamatsu M, Smith ML, Lung FD, Duba D, Roller PP, et al. Characterization of p21Cip1/Waf1 peptide domains required for cyclin E/Cdk2 and PCNA interaction. Oncogens 1996;12:595-607.
23. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994;266:1376-80.
24. Chen IT, Smith ML, O'Connor PM, Fornace AJJ. Direct interaction of Gadd45 with PCNA and evidence for competitive interaction of Gadd45 and p21Waf1/Cip1 with PCNA. Oncogene 1995;11:1931-7.
25. Macklis RM, Beresford BA, Palayoor S, Sweeney S, Humm JL. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int J Radiat Oncol Biol Phys 1993;27:643-50.
26. Macklis RM, Lin JY, Beresford BA, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis. Radiat Res 1992;130:220-6.
27. McGowan AJ, Ruiz-Ruiz MC, Gorman AM, Lopez Rivas A, Cotter TG. Reactive oxygen intermediates (ROI): common mediator(s) of poly(ADP-ribose) polymerase (PARP) cleavage and apoptosis. FEBS Lett 1996;392:299-303.
28. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, et al. Yama/CPP32B, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
29. Gu Y, Sarnicki C, Aldape RA, Livingston DJ, Su MS-S. Cleavage of poly(ADP-ribose) polymerase by interleukin-1B converting enzyme and its homologs TX and Nedd-2. J Biol Chem 1995;270(32):18715-8.
30. Soldatenkov VA, Prasad S, Notario V, Dritschilo A. Radiation-induced apoptosis of ewing's sarcoma cells: DNA fragmentation and proteolysis of poly(ADP-ribose) polymerase. Cancer Res 1995;55:4240-2.
31. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-85.
32. Chiarugi V, Ruggiero M. Role of three cancer "master genes" p53, bcl2 and c-myc on the apoptotic process. Tumori 1996; 82:205-9.
33. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
34. Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH, Kim HR. bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res 1995;55:4520-4.
35. Matsushima H, Hosaka Y, Suzuki M, Mizutani T, Ishizuka H, Kawabe K. bcl-2 expression on prostate cancer and its relationship to cell cycle and prognosis. Int J Urol 1996;3:113-7.
36. Caron-Leslie LA, Evans RB, Cidlowski JA. Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulated apoptosis in S49 cells. FASEB J 1994;8:639-45.
37. Marken JS, Bajorath J, Edwards CP, Farr AG, Schieven GL, Hellstrom I, et al. Membrane topology of the L6 antigen and identification of the protein epitope recognized by the L6 monoclonal antibody. J Biol Chem 1994;269:7397-401.
38. Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellstrom KE. Monoclonal antibodies raised against human lung carcinomas. Cancer Res 1986;46:3917-23.
39. Liu AY, Robinson RR, Hellstrom KE, Murray ED Jr., Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci U S A 1987;84:3439-43.
40. Li M, Meares CF. Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjug Chem 1993;4:275-83.
41. Li M, Meares CF, Zhong GR, Miers L, Xiong CY, DeNardo SJ. Labeling monoclonal antibodies with 90yttrium- and 111indium-DOTA chelates: a simple and efficient method. Bioconjug Chem 1994;5:101-4.
42. DeNardo SJ, Zhong G-R, Salako Q, Li M, DeNardo GL, Meares CF. Pharmacokinetics of chimeric L6 conjugated to 111In- and 90Y-DOTA-peptide in tumor bearing mice. J Nucl Med 1995;36:829-36.
43. Adams GP, DeNardo SJ, Deshpande SV, DeNardo GL, Meares CF, McCall MJ, et al. Effect of mass of 111In-benzyl-EDTA monoclonal antibody on hepatic uptake and processing in mice. Cancer Res 1989;49:1707-11.
44. DeNardo SJ, Kukis DL, Miers LA, Winthrop MD, Kroger LA, Salako Q, et al. Yttrium-90-DOTA-peptide ChL6 radioimmunoconjugate: Efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts. J Nucl Med 1997; in press.
45. Mattes MJ, Major PP, Goldenberg DM, Dion AS, Hutter RV, Klein KM. Patterns of antigen distribution in human carcinomas. Cancer Res 1990;50:880s-4s.
46. Gumerlock PH, Edwards BF, Deitch AD, Meyers FJ. Human renal clear cell carcinoma: establishment and characterization of a new cell line (G-2101). In Vitro Cell Dev Biol 1988;24:429-34.
47. DeNardo SJ, Gumerlock PH, Winthrop MD, Mack PC, Chi SG, Lamborn KR, et al. Yttrium-90 chimeric L6 therapy of human breast cancer in nude mice and apoptosis-related messenger RNA expression. Cancer Res 1995;55:5837s-41s.
48. Fishman JR, Gumerlock PH, Meyers FJ, deVere White RW. Quantitation of NM23 expression in human prostate tissues. J UrolI 1994;152:202-7.
49. Borchers H, Meyers FJ, Gumerlock PH, Stewart SL, deVere White RW. NM23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: altered expression in combined androgen blockaded carcinomas. J Urol 1996; 155:2080-4.
50. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994;86:926-33.
51. Tricoli JV, Gumerlock PH, Yao JL, Chi S-G, D'Souza SA, Nestok BR, et al. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes, Chromosom Cancer 1996;15:108-14.
52. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
53. Gumerlock PH, Meyer FJ, Kokoris SP, Wong G, McCormick FP, deVere White RW. RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression. Anal Biochem 1989;180:158-68.
54. Towbin H, Staehlin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979;76:4350-4.
55. Saunders KA, Madewell BR, Oreffo Vl, Kraegel SA, Gumerlock PH. Nucleotide sequence of canine c-N-ras: codons 1 to 71. Am J Vet Res 1992;53:600-3.
56. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A 1995;92:5436-40.
57. Ross HJ, Canada AL, Antoniono RJ, Redpath JL. High and low dose rate irradiation have opposing effects on cytokine gene expression in human glioblastoma cell lines. Eur J Cancer 1997;33(1):144-52.
58. Bracey TS, Miller JC, Preece A, Paraskeva C. Gamma-radiation-induced apoptosis in human colorectal adenoma and carcinoma cell lines can occur in the absence of wild type p53. Oncogene 1995;10:2391-6.
59. Kramer EL. PCP, AIDS and nuclear medicine. J Nucl Med 1994;35:1034-7.
60. Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res 1996;56:2998-3003.
61. Ishioka C, Englert C, Winge P, Yan YX, Engelstein M, Friend SH. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 1995;10:1485-92.
62. D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, Russell E, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992;7:339-46.
63. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996;15: 827-38.
64. Ozbun MA, Butel JS. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Mv Cancer Res 1995;66:71-141.
65. Dou QP, Lui VW. Failure to dephosphorylate retinoblastoma protein in drug-resistant cells. Cancer Res 1995;55:5222-5.
66. Hawkins DS, Demers GW, Galloway DA. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 1996;56:892-8.
67. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, et al. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nature Med 1996;2:72-9.
68. DeNardo SJ, Kroger LA, Lamborn KR, Miers LA, O'Donnell R, Kukis DL, et al. Importance of temporal relationships in combined modality radioimmunotherapy of breast cancer. Cancer 1997;80:2583-90.
69. Reed JC, Cuddy M, Haldar S, Croce C, Nowell P, Makover D, et al. BCL2-mediated tumorigenicity of a human T-lymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc Natl Acad Sci U S A 1990;87:3660-4.
70. Morelli S, Alama A, Quattrone A, Gong L, Copreni E, Canti G, et al. Oligonucleotides induce apoptosis restricted to the t(14;*8) DHL-4 cell line. Anticancer Drug Des 1996;11:1-14.
71. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
72. Keith FJ, Bradbury DA, Zhu YM, Russell NH. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. Leukemia 1995;9:131-8.
73. Reed M, Woelker B, Wang P, Wang Y, Anderson ME, Tegtmeyer P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc Natl Acad Sci U S A 1995;92:9455-9.